The cancer-associated fibroblasts and drug resistance

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 11, 2015, Pages 2112-2119

  Li, X Y ^a   Hu, S Q ^b   Xiao, L ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer associated fibroblasts; Drug resistance; Signaling pathways

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; CHEMOKINE RECEPTOR CXCR4; INTERLEUKIN 6; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR RECEPTOR; CXCR4 PROTEIN, HUMAN; HGF PROTEIN, HUMAN; MET PROTEIN, HUMAN; SCATTER FACTOR;

CANCER ASSOCIATED FIBROBLAST; CANCER STEM CELL; DRUG RESISTANCE; FIBROBLAST; HUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; DRUG EFFECTS; EPITHELIUM CELL; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; FIBROBLASTS; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERLEUKIN-6; NEOPLASMS; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOPLASTIC STEM CELLS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, CXCR4; TUMOR MICROENVIRONMENT;

EID: 84942251181     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. HAZLEHURST LA, LANDOWSKI TH, DALTON WS. Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 2003; 22: 7396-7402.
2. IACOBUZIO-DONAHUE CA, RYU B, HRUBAN RH, KERN SE. Exploring the host desmoplastic response to pancreatic carcinoma. Am J Pathol 2002; 160: 91-99.
3. FARMER P, BONNEFOI H, ANDERLE P, CAMERON D, WIRAPATI P, BECETTE V, ANDRÉ S, PICCART M, CAMPONE M, BRAIN E, MACGROGAN G, PETIT T, JASSEM J, BIBEAU F, BLOT E, BOGAERTS J, AGUET M, BERGH J, IGGO R, DELORENZI M. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 2009; 15: 68-74.
4. CUKIERMAN E, KHAN DR. The benefits and challenges associated with the use of drug delivery systems in cancer therapy. Biochem Pharmacol 2010; 80: 762-770.
5. ORIMO A, WEINBERG RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 2006; 5: 1597-1601.
6. MUELLER MM, FUSENIG NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004; 4: 839-849.
7. JOHANSSON AC, ANSELL A, JERHAMMAR F, LINDH MB, GR ÉNMAN R, MUNCK-WI K LAND E, ÖS TMAN A, ROBERG K. Cancer-associated fibroblasts induce matrix metalloproteinase-mediated cetuximab resistance in head and neck squamous cell carcinoma cells. Mol Cancer Res 2012; 10: 1158-1168.
8. HWANG RF, MOORE T, ARUMUGAM T, RAMACHANDRAN V, AMOS KD, RIVERA A, JI B, EVANS DB, LOGSDON CD. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68: 918-926.
9. WANG W, LI Q, YAMADA T, MATSUMOTO K, MATSUMOTO I, ODA M, WATANABE G, KAYANO Y, NISHIOKA Y, SONE S, YANO S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 2009; 15: 6630-6638.
10. KERBEL RS. A cancer therapy resistant to resistance. Nature 1997; 390: 335-336.
11. WORTHLEY DL, GIRAUD AS, WANG TC. Stromal fibroblasts in digestive cancer. Cancer Microenviron 2010; 3: 117-125.
12. GONDA TA, VARRO A, WANG TC, TYCKO B. Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anticancer therapy? Semin Cell Dev Biol 2010; 21: 2-10.
13. LOEFFLER M, KRÜGER JA, NIETHAMMER AG, REISFELD RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006; 116: 1955-1962.
14. KHARAZIHA P, RODRIGUEZ P, LI Q, RUNDQVIST H, BJÖRKLUND AC, AUGSTEN M, ULLÉN A, EGEVAD L, WIKLUND P, NILSSON S, KROEMER G, GRANDER D, PANARETAKIS T. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012; 3: e262.
15. CRAWFORD Y, KASMAN I, YU L, ZHONG C, WU X, MODRUSAN Z, KAMINKER J, FERRARA N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009; 15: 21-34.
16. PORTER DC, FARMAKI E, ALTILIA S, SCHOOLS GP, WEST DK, CHEN M, CHANG BD, PUZYREV AT, LIM CU, ROKOW-KITTELL R, FRIEDHOFF LT, PAPAVASSILIOU AG, KALURUPALLE S, HURTEAU G, SHI J, BARAN PS, GYORFFY B, WENTLAND MP, BROUDE EV, KIARIS H, RONINSON IB. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumorpromoting paracrine activities. Proc Natl Acad Sci USA 2012; 109: 13799-13804.
17. ATLASI Y, MOWLA SJ, ZIAEE SA, BAHRAMI AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer 2007; 120: 1598-1602.
18. LI X, LEWIS MT, HUANG J, GUTIERREZ C, OSBORNE CK, WU MF, HILSENBECK SG, PAVLICK A, ZHANG X, CHAMNESS GC, WONG H, ROSEN J, CHANG JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
19. AL-HAJJ M, WICHA MS, BENITO-HERNANDEZ A, MORRISON SJ, CLARKE MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
20. VISVADER JE, LINDEMAN GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
21. FRANK NY, SCHATTON T, FRANK MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
22. BAO B, AHMAD A, AZMI AS, ALI S, SARKAR FH. Cancer stem cells (CSCs) and mechanisms of their regulation: implications for cancer therapy. Curr Protoc Pharmacol 2013; 14: Unit 14.25.
23. BAO S, WU Q, MCLENDON RE, HAO Y, SHI Q, HJELMELAND AB, DEWHIRST MW, BIGNER DD, RICH JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
24. YANG ZJ, WECHSLER-REYA RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007; 11: 3-5.
25. ALISON MR, LIM SM, NICHOLSON LJ. Cancer stem cells: problems for therapy? J Pathol 2011; 223: 147-161.
26. DEANM, FOJO T, BATES S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284.
27. TSUYADA A, CHOW A, WU J, SOMLO G, CHU P, LOERA S, LUU T, LI AX, WU X, YE W, CHEN S, ZHOU W, YU Y, WANG YZ, REN X, LI H, SCHERLE P,KUROKI Y, WANG SE. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res 2012; 72: 2768-2779.
28. KINUGASA Y, MATSUI T, TAKAKURA N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014; 32: 145-156.
29. ADISETIYO H, LIANG M, LIAO CP, JEONG JH, COHEN MB, ROY-BURMAN P, FRENKEL B. Dependence of castration-resistant prostate cancer (CRPC) stem cells on CRPC-associated fibroblasts. J Cell Physiol 2014; 229: 1170-1176.
30. LOTTI F, JARRAR AM, PAI RK, HITOMI M, LATHIA J, MACE A, GANTT GA JR, SUKHDEO K, DEVECCHIO J, VASANJI A, LEAHY P, HJELMELAND AB, KALADY MF, RICH JN. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med 2013; 210: 2851-2872.
31. MINK SR, VASHISTHA S, ZHANG W, HODGE A, AGUS DB, JAIN A. Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res 2010; 8: 809-820.
32. YAO Z, FENOGLIO S, GAO DC, CAMIOLO M, STILES B, LINDSTED T, SCHLEDERER M, JOHNS C, ALTORKI N, MITTAL V, KENNER L, SORDELLA R. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci USA 2010; 107: 15535-15540.
33. YANG AD, FAN F, CAMP ER, VAN BUREN G, LIU W, SOMCIO R, GRAY MJ, CHENG H, HOFF PM, ELLIS LM. Chronic oxaliplatin resistance induces epithelialto-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res 2006; 12: 4147-4153.
34. KAJIYAMA H, SHIBATA K, TERAUCHI M, YAMASHITA M, INO K, NAWA A, KIKKAWA F. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277-283.
35. MANI SA, GUO W, LIAO MJ, EATON EN, AYYANAN A, ZHOU AY, BROOKS M, REINHARD F, ZHANG CC, SHIPITSIN M, CAMPBELL LL, POLYAK K, BRISKEN C, YANG J, WEINBERG RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
36. GAO MQ, KIM BG, KANG S, CHOI YP, PARK H, KANG KS, CHO NH. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 2010; 123: 3507-3514.
37. GIANNONI E, BIANCHINI F, MASIERI L, SERNI S, TORRE E, CALORINI L, CHIARUGI P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res 2010; 70: 6945-6956.
38. SHINTANI Y, ABULAITI A, KIMURA T, FUNAKI S, NAKAGIRI T, INOUE M, SAWABATA N, MINAMI M, MORII E, OKUMURA M. Pulmonary fibroblasts induce epithelial mesenchymal transition and some characteristics of stem cells in non-small cell lung cancer. Ann Thorac Surg 2013; 96: 425-433.
39. PENUELAS S, ANIDO J, PRIETO-SANCHEZ RM, FOLCH G, BARBA I, CUARTAS I, GARCÍA-DORADO D, POCA MA, SAHUQUILLO J, BASELGA J, SEOANE J. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 2009; 15: 315-327.
40. NAKA K, HOSHII T, MURAGUCHI T, TADOKORO Y, OOSHIO T, KONDO Y, NAKAO S, MOTOYAMA N, HIRAO A. TGFbeta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
41. YU Y, XIAO CH, TAN LD, WANG QS, LI XQ, FENG YM. Cancer-associated fibroblasts induce epithelialmesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer 2014; 110: 724-732.
42. ŠVASTOVÁ E, HULÍKOVÁ A, RAFAJOVÁ M, ZAT'OVICOVÁ M, GIBADULINOVÁ A, CASINI A, CECCHI A, SCOZZAFAVA A, SUPURAN CT, PASTOREK J, PASTOREKOVÁ S. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004; 577: 439-445.
43. SWIETACH P, HULIKOVA A, VAUGHAN-JONES RD, HARRIS AL. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene 2010; 29: 6509-6521.
44. FIASCHI T, GIANNONI E, TADDEI ML, CIRRI P, MARINI A, PINTUS G, NATIVI C, RICHICHI B, SCOZZAFAVA A, CARTA F, TORRE E, SUPURAN CT, CHIARUGI P. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle 2013; 12: 1791-1801.
45. DONTU G, JACKSON KW, MCNICHOLAS E, KAWAMURA MJ, ABDALLAH WM, WICHA MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004; 6: R605-615.
46. HEUCHEL R1, BERG A, TALLQUIST M, AHLÉN K, REED RK, RUBIN K, CLAESSON-WELSH L, HELDIN CH, SORIANO P. Platelet-derived growth factor b receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3. kinase signaling. Proc Natl Acad Sci USA 1999; 96: 11410-11415.
47. HELDIN CH. Autocrine PDGF stimulation in malignancies. Ups J Med Sci 2012; 117: 83-91.
48. HELDIN CH, RUBIN K, PIETRAS K, OSTMAN A. High interstitial fluid pressuredan obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-813.
49. PIETRAS K, RUBIN K, SJOBLOM T, BUCHDUNGER E, SJÖQUIST M, HELDIN CH, OSTMAN A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002; 62: 5476-5484.
50. CURTI BD. Physical barriers to drug delivery in tumors. Crit Rev Oncol Hematol 1993; 14: 29-39.
51. PIETRAS K, OSTMAN A, SJOQUIST, M, BUCHDUNGER E, REED RK, HELDIN CH, RUBIN K. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929-2934.
52. RUBIN K, SJOQUIST M, GUSTAFSSON AM, ISAKSSON B, SALVESSEN G, REED RK. Lowering of tumoral interstitial fluid pressure by prostaglandin E(1) is paralleled by an increased uptake of (51)Cr-EDTA. Int J Cancer 2000; 86: 636-643.
53. HWANG RF, YOKOI K, BUCANA CD, TSAN R, KILLION JJ, EVANS DB, FIDLER IJ. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res 2003; 9: 6534-6544.
54. PIETRAS K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004; 31: 18-23.
55. FORSBERG K, VALYI-NAGY I, HELDIN CH, HERLYN M, WESTERMARK B. Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 1993; 90: 393-397.
56. MICKE P, OSTMAN A. Tumour-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45: S163-S175.
57. SUMIDA T, KITADAI Y, SHINAGAWA K, TANAKA M, KODAMA M, OHNISHI M, OHARA E, TANAKA S, YASUI W, CHAYAMA K. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int J Cancer 2011; 128: 2050-2062.
58. PIETRAS K, SJÖBLOM T, RUBIN K, HELDIN CH, OSTMAN A. PDGF receptors as cancer drug targets. Cancer Cell 2003; 3: 439-443.
59. ONOYAMA M, KITADAI Y, TANAKA Y, YUGE R, SHINAGAWA K, TANAKA S, YASUI W, CHAYAMA K. Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer. Neoplasia 2013; 15: 1391-1399.
60. OLIVE KP, JACOBETZ MA, DAVIDSON CJ, GOPINATHAN A, MCINTYRE D, HONESS D, MADHU B, GOLDGRABEN MA, CALDWELL ME, ALLARD D, FRESE KK, DENICOLA G, FEIG C, COMBS C, WINTER SP, IRELAND-ZECCHINI H, REICHELT S, HOWAT WJ, CHANG A, DHARA M, WANG L, RÜCKERT F, GRÜTZMANN R, PILARSKY C, IZERADJENE K, HINGORANI SR, HUANG P, DAVIES SE, PLUNKETT W, EGORIN M, HRUBAN RH, WHITEBREAD N, MCGOVERN K, ADAMS J, IACOBUZIO-DONAHUE C, GRIFFITHS J, TUVESON DA. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324:1457-1461.
61. ZARNEGAR R, MICHALOPOULOS GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol 1995; 129: 1177-1180.
62. Jiang WG. Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies. Curr Oncol 2007; 14: 66-69.
63. LURAGHI P, REATO G, CIPRIANO E, SASSI F, ORZAN F, BIGATTO V, DE BACCO F, MENIETTI E, HAN M, RIDEOUT WM 3RD, PERERA T, BERTOTTI A, TRUSOLINO L, COMOGLIO PM, BOCCACCIO C. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014; 74: 1857-1869.
64. OKUDA K, SASAKI H, YUKIUE H, YANO M, FUJII Y. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci 2008; 99: 2280-2285.
65. CAPPUZZO F, MARCHETTI A, SKOKAN M ROSSI E, GAJAPATHY S, FELICIONI L, DEL GRAMMASTRO M, SCIARROTTA MG, BUTTITTA F, INCARBONE M, TOSCHI L, FINOCCHIARO G, DESTRO A, TERRACCIANO L, RONCALLI M, ALLOISIO M, SANTORO A, VARELLA-GARCIA M. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27: 1667-1674.
66. YAMADA T, MATSUMOTO K, WANG W, LI Q, NISHIOKA Y, SEKIDO Y, SONE S, YANO S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010; 16: 174-183.
67. YAMADA T, TAKEUCHI S, KITA K, BANDO H, NAKAMURA T, MATSUMOTO K, YANO S. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol 2012; 7: 272-280.
68. WILSON TR, FRIDLYAND J, YAN Y, PENUEL E, BURTON L, CHAN E, PENG J, LIN E, WANG Y, SOSMAN J, RIBAS A, LI J, MOFFAT J, SUTHERLIN DP, KOEPPEN H, MERCHANT M, NEVE R, SETTLEMAN J. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012; 487: 505-509.
69. STRAUSSMAN R, MORIKAWA T, SHEE K, BARZILY-ROKNI M, QIAN ZR, DU J, DAVIS A, MONGARE MM, GOULD J, FREDERICK DT, COOPER ZA, CHAPMAN PB, SOLIT DB, RIBAS A, LO RS, FLAHERTY KT, OGINO S, WARGO JA, GOLUB TR. Tumor microenvironment elicits innate RAF-inhibitor resistance through HGF secretion. Nature 2012; 487: 500-504.
70. TEICHER BA, FRICKER SP. CXCL12 (SDF-1)/CXCR4 Pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931.
71. WEEKES CD, SONG D, ARCAROLI J, WILSON LA, RUBIOVIQUEIRA B, CUSATIS G, GARRETT-MAYER E, MESSERSMITH WA, WINN RA, HIDALGO M. STROMAL cell-derived factor 1mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia 2012; 14: 690-701.
72. SINGH S, SRIVASTAVA SK, BHARDWAJ A, OWEN LB, SINGH AP. CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy. Br J Cancer 2010; 103: 671-1679.
73. DOMANSKA UM, TIMMER-BOSSCHA H, NAGENGAST WB, OUDE MUNNINK TH, KRUIZINGA RC, ANANIAS HJ, KLIPHUIS NM, HULS G, DE VRIES EG, DE JONG IJ, WALENKAMP AM. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 2012; 14: 709-718.
74. SHIOZAWA Y, PEDERSEN EA, HAVENS AM, JUNG Y, MISHRA A, JOSEPH J, KIM JK, PATEL LR, YING C, ZIEGLER AM, PIENTA MJ, SONG J, WANG J, LOBERG RD, KREBSBACH PH, PIENTA KJ, TAICHMAN RS. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011; 121: 1298-1312.
75. BURGER JA, STEWART DJ, WALD O, PELED A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther 2011; 11: 621-630.
76. RIGHI E, KASHIWAGI S, YUAN J, SANTOSUOSSO M, LEBLANC P, INGRAHAM R, FORBES B, EDELBLUTE B, COLLETTE B, XING D, KOWALSKI M, MINGARI MC, VIANELLO F, BIRRER M, ORSULIC S, DRANOFF G, POZNANSKY MC. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 2011; 71: 5522-5534.
77. STUDEBAKER AW, STORCI G, WERBECK JL, SANSONE P, SASSER AK, TAVOLARI S, HUANG T, CHAN MW, MARINI FC, ROSOL TJ, BONAFÉ M, HALL BM. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 9087-9095.
78. CATLETT-FALCONE R, LANDOWSKI TH, OSHIRO MM, TURKSON J, LEVITZKI A, SAVINO R, CILIBERTO G, MOSCINSKI L, FERNÁNDEZ-LUNA JL, NUÑEZ G, DALTON WS, JOVE R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
79. GAO SP, MARK KG, LESLIE K, PAO W, MOTOI N, GERALD WL, TRAVIS WD, BORNMANN W, VEACH D, CLARKSON B, BROMBERG JF. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-3856.
80. GILBERT LA, HEMANN MT. DNA damage-mediated induction of a chemoresistant niche. Cell 2010; 143: 355-366.